Background. Increased levels of collagen types I, III and V are found in strictures of patients with Crohn's disease (CD) compared with normal gut tissue. Type IV collagen is present in the basement membranes, basal lamina, retina and cornea. Elevated levels of antibody to Klebsiella pneumoniae are found in both active CD and active ankylosing spondylitis (AS) patients compared with healthy controls.
Crohn's disease (CD) is an in¯ammatory disorder affecting the gastrointestinal tract, particularly the ileocaecal region. It is associated with increased collagen deposition, which leads to the development of strictures, and these often occur early in the course of the disease w1x. The pathogenesis of stricture formation in the gastrointestinal tract is unknown. The narrowing of the lumen of the bowel due to the accumulation of collagen can cause partial or complete obstruction, which then requires surgical correction. Immunohistochemical studies have shown that the collagens involved in CD are usually of types I, III and V w2x, which are present in the lamina propria, muscularis mucosae and muscularis propria respectively w3x.
Ankylosing spondylitis (AS) can be considered a reactive arthritis following Klebsiella pneumoniae infection in HLA-B27-positive patients, on the basis of ®ndings of raised anti-Klebsiella antibodies and the presence of molecular mimicry between the HLA-B27 molecule and bacterial antigens w4,5x. Amino acid homology has been described between the extracellular starch-induced enzyme pullulanase of K. pneumoniae and collagen types I, III and IV w6x. Histological changes in thigh muscle biopsies of AS patients have been reported w7x in which type III collagen is present. Type IV collagen is found in the basement membranes, basal lamina, retina and cornea w8x. Furthermore, elevated levels of IgG and IgA antibodies to both type I and type IV collagen have been demonstrated in AS patients w6x.
Crohn's disease-like lesions have also been shown to be present in AS patients w9x. Spondyloarthropathy occurs in at least 20% of in¯ammatory bowel disease (IBD) patients w10x. Speci®c elevations of antibodies to Klebsiella in CD patients were ®rst reported in 1987 w11x. This observation was subsequently con®rmed when an extensive study involving three pathogenic microbes and 10 anaerobic isolates of the normal bowel¯ora showed elevated titres of antibodies to Klebsiella in both CD and AS patients, but no such elevations were found against Proteus, Escherichia coli or any of 10 anaerobic bacteria w12x. Previously, our group has shown that RA patients have elevated levels of antibodies to Proteus mirabilis and not to Klebsiella, whereas AS patients have elevated immune responses to Klebsiella and not to P. mirabilis w13x. Furthermore, class-speci®c antibodies to capsular serotypes of K. pneumoniae have been reported to be increased in both active CD patients and active AS patients w14x.
The aims of this study were three-fold: (i) to determine whether the levels of antibodies to collagen types I, III, IV and V and to K. pneumoniae are increased in active patients with CD and AS compared with healthy controls; (ii) to determine if the pattern of antibody class responses to these collagen types and K. pneumoniae is different in patients with late CD compared with those with an early diagnosis of the disease; and (iii) most importantly, to determine if there is a correlation between anti-collagen and K. pneumoniae antibodies among CD and AS patients.
Patients and methods

Patients
In total, serum samples from 93 subjects were studied. Sera were obtained from nine patients with earlystage CD (®ve males, four females) (mean age 30 yr, range 15±77 yr); 10 patients with late-stage CD (seven males, three females) (mean age 31 yr, range 20±52 yr). The early-and late-stage CD patients attended the Gastroenterology Outpatients Clinic at King's College Hospital. Sera were also obtained from 12 patients with late CD (eight males, four females) (mean age 46 yr, range 17±79 yr) attending the Gastroenterology Outpatients Clinic at the Middlesex Hospital. Sera from 36 unrelated HLA-B27-positive patients with active AS (24 males, 12 females) (mean age 46 yr, range 31±70 yr) satisfying the Rome±New York diagnostic criteria and having an erythrocyte sedimentation rate (ESR) )15 mmuh were obtained from the AS Research Clinic at the Middlesex Hospital, London. All AS patients were being treated with sulphasalazine-EN (0.5±2.0 g daily) and a low-starch diet w15x. In addition, sera from 26 control subjects were supplied by the Blood Transfusion Service in London (14 males, 12 females) (mean age 41 yr, range 30±59 yr). The general characteristics of the study groups are shown in Table 1 .
Diagnosis of Crohn's disease
The diagnosis of CD was made using the standard St Marks criteria w16x, with a Harvey±Bradshaw score ELISA studies on collagen types I, III, IV and V. The ELISA protocol used in the study was similar to that used by several investigators in this ®eld of study in that antibody levels are reported in OD units rather than concentrations w5,13x. Ninety-six-well,¯at-bottomed polystyrene microtitre plates (Dynatech, Billingshurst, UK) were coated with 200 ml of 1 mguml collagen solution wcollagenqcarbonate buffer (0.05 M), pH 9.6x and incubated overnight at 48C. The plates were then washed three times with PBS±Tween and 300 ml of blocking solution in PBS was added to each well w2% (wuv) casein, 0.1% (vuv) Tween 20 in PBSx, and the plates were incubated for 2 h at room temperature. Excess blocking solution was removed and 200-ml serum samples (test or control) diluted 1u200 in PBS±Tween were added in duplicate. Plates were incubated at room temperature for 2 h, followed by the addition of 200 ml peroxidase-conjugated rabbit anti-human IgM, IgG or IgA serum (Dako) diluted 1u500 in PBS±Tween, and incubated for a further 2 h at room temperature. Development of the colorimetric assay also took place at room temperature for 20 min after the addition of 200 ml per well of 0.5 mguml 2,29-azinobis (3-ethylbenz-thiazoline-6-sulphonic acid (Sigma) in citrate phosphate buffer, pH 4.1, containing 0.98 mM H 2 O 2 (Sigma). The reaction was stopped with 100 ml of 2 mguml sodium¯uoride (Sigma) and the OD was measured at a wavelength of 630 nm with a micro-ELISA plate reader (Dynatech MR600). All assays were carried out under code, in that the tester did not know whether the sera came from patients or controls, and the results were expressed as OD units " S.E.
Bacterial ELISA. K. pneumoniae suspended in carbonate buffer (0.05 M), pH 9.6, was adsorbed onto 96-well¯at bottomed microtitre plates overnight at 48C in 200-ml volumes. The plates were then washed and saturated with a blocking solution w0.1% (wuv) bovine serum albumin, 0.05% (vuv) Tween 20x in PBS and incubated for 1 h at 378C. The rest of the ELISA procedure was carried out as mentioned above except that the plates were incubated at 378C for 1 h after the addition of the individual serum samples and the peroxidase-conjugated antibodies.
Statistical analysis. The mean OD units for IgM, IgG and IgA antibodies against K. pneumoniae and collagen types I, III, IV and V in the various patient groups and the control group were compared using Student's t-test. Differences in levels of the immunoglobulin classes were assessed by comparing the number of individuals in each group having OD units greater than the 95% con®dence limits for the control group (one-tailed test), using the x 2 test with Yates' correction. The correlation coef®cient (r) was calculated with the analytical program Minitab, release 5.1 (Pearson's correlation coef®cient), and the reproducibility of the antibody assay for each sample was measured by calculating the coef®cient of variation. Individual samples were plotted (scatter graph) and histograms drawn using the statistical package Prism 3.0.
Results
Levels of IgM, IgG and IgA antibodies to K. pneumoniae (K50) and to each of the four collagen types were measured by ELISA in CD and AS patients and healthy controls. Data for the CD patients from the two centres were combined and analysed as one group and as earlyand late-CD groups.
Antibodies to K. pneumoniae Levels of antibody to K. pneumoniae (K50) of IgM class (Fig. 1A) were signi®cantly higher in CD (mean " S.E. OD units) (0.39" 0.05; t s 6.6, P -0.001) and AS patients (0.24 " 0.03; t s 6.2, P -0.001), IgG levels (Fig. 1B) were signi®cantly higher in CD patients (0.32 " 0.05; t s 5.3, P -0.001) and the AS group (0.30 " 0.05; t s 4.7, P -0.001), and IgA levels were signi®cantly higher (Fig. 1C) in CD (0.07" 0.02; t s 21.0, P -0.001) and AS patients (0.05" 0.01; t s 13.9, P -0.001) than in the healthy controls. Levels of IgM, IgG and IgA antibodies to K. pneumoniae in early and late CD were analysed in comparison with controls, and the OD units (mean "S.E.) are shown in Table 2 . There was no difference between early or late CD patients in the mean levels of IgM, IgG and IgA class antibodies to K. pneumoniae. However, IgM anti-K. pneumoniae antibody levels were higher in early CD (t s 7.5, P -0.001) and late CD (t s 9.8, P -0.001) than in control subjects; levels of IgG anti-K. pneumoniae antibody were higher in early CD (t s 7.7, P -0.001) and late CD (t s 4.2, P -0.001) than in controls, and levels of IgA anti-K. pneumoniae antibody were higher in early CD patients (t s 4.8, P -0.001) and late CD patients (t s 2.9, P -0.01) than in control subjects.
Antibodies to collagen types I, III, IV and V IgM, IgG and IgA levels to the four collagen types were measured in CD and AS patients (Fig. 2) .
Compared with the individual control groups, CD patients had signi®cantly higher levels (mean " S.E. OD units) of IgM antibodies to collagen types I (0.26" 0.02; t s 10.4, P -0.001), III (0.22 "0.03; t s 7.1, P -0.001), IV (0.1 " 0.01; t s 9.3, P -0.001) and V (0.49" 0.04; t s 8.7, P -0.001), signi®cantly higher levels of IgG antibodies to collagen types I (0.64" 0.08; t s 5.6, P -0.001), III (0.57 "0.07; t s 5.7, P -0.001), IV (0.49 "0.07; t s 5.1, P -0.001) and V (0.38" 0.05; t s 5.1, P -0.001), and signi®cantly higher levels of IgA antibodies to collagen types I (0.08 "0.01; t s 4.9, P -0.001), III (0.15 "0.02; t s 6.2, P -0.001), IV (0.07 "0.01; t s 5.4, P -0.001) and V (0.1 " 0.02; t s 5.8, P -0.001).
Compared with the healthy controls, AS patients had signi®cantly higher levels of IgM antibodies to collagen types I (0.21 "0.02; t s 8.5, P-0.001), III (0.18 "0.02; t s 7.0, P -0.001), IV (0.07 "0.01; t s 5.6, P -0.001) and V (0.5 "0.04; t s 8.5, P -0.001), signi®cantly higher levels of IgG antibodies to collagen types I (0.57" 0.07; t s 5.5, P -0.001), III (0.58 "0.06; t s 6.3, P -0.001), IV (0.4 "0.06; t s 4.2, P -0.001) and V (0.35 " 0.04; t s 5.2, P -0.001), and signi®cantly higher levels of IgA antibodies to collagen types I (0.07" 0.02; t s 3.0, P -0.001), III (0.12 "0.01; t s 6.3, P -0.001) and V (0.1 " 0.02; t s 4.3, P -0.001). There was no signi®cant difference in antibody levels of IgA antibodies to collagen type IV in the AS patients compared with the control group.
Levels of IgM, IgG and IgA antibodies to collagen types I, III, IV and V in early and late CD were analysed in comparison with controls, and the OD units (mean "S.E.) are shown in Table 2 .
There was no difference between early and late CD in the mean levels of antibodies of the different classes to the individual collagens. Compared with the healthy control group, the group of patients with early CD had signi®cantly higher levels of IgM antibodies to collagen types I (t s 7.4, P -0.001), III (t s 7.4, P -0.001), IV (t s 9.6, P -0.001) and V (t s 5.3, P -0.001).
The group of patients with early CD also had signi®cantly higher values than the healthy control group for levels of IgG antibodies to collagen types I (t s 4.2, P -0.001), III (t s 5.0, P -0.001), IV (t s 3.8, P -0.001.001) and V (t s 4.7, P -0.001) and in levels of IgA antibodies to collagen types I (t s 10.4, P -0.001), III (t s 9.1, P -0.001), IV (t s 3.1, P -0.001) and V (t s 9.0, P -0.001).
The group of patients with late CD had signi®cantly higher levels than the healthy control group for IgM antibodies to collagen types I (t s 14.2, P -0.001), III (t s 6.9, P -0.001), IV (t s 7.7, P -0.001) and V (t s 9.9, P-0.001.001), for IgG antibodies to collagen types I (t s 5.2, P -0.001), III (t s 5.5, P -0.001), IV (t s 4.8, P -0.001) and V (t s 4.6, P -0.001.001), and for IgA antibodies to collagen types I (t s 5.8, P -0.001), III (t s 5.4, P -0.001), IV (t s 4.7, P -0.001) and V (t s 5.4, P -0.001).
Patients with immunoglobulin levels above the 95% con®dence limits Numbers of patients with levels of IgM, IgG and IgA antibodies to each of the collagen types and to K. pneumoniae that were above the 95% con®dence limit of the control population were determined in the disease and control groups (one-tailed test; Table 3) and statistical signi®cances were assessed using the x 2 test with Yates' correction (Table 4) . Compared with the controls, signi®cantly more early and late CD patients showed levels of antibodies to collagens I, III, IV and V and to K. pneumoniae that were above the 95% con®dence. However, levels of IgG and IgA antibodies above this limit were not found in patients with early CD (Table 4) . Furthermore, the levels of signi®cance of the increases in the numbers of late CD and AS patients with antibody levels above the limit compared with the control group were similar for all four types of collagen, and particularly for K. pneumoniae, for all three classes of immunoglobulin, except IgG to type IV collagen in AS patients. There was no statistically signi®cant difference between levels of antibody to any of the collagen types or to K. pneumoniae in early or late CD patients when they were strati®ed according to high or low CRP or to high or low ESR.
Five patients diagnosed with early CD and who also had ileal strictures, one of whom had AS and was HLA-B27-positive, had elevated levels of IgM antibodies to collagen types I, III, IV and V, whilst levels of IgG and IgA antibodies to collagen types I, III and V were above the 95% con®dence limit. Furthermore, all ®ve patients had levels of IgM and IgG antibodies to K. pneumoniae that were above the 95% con®dence limits, whereas only two had IgA levels above the limits; one of these patients had AS. Four out of the ®ve patients were male, three of whom were on prednisolone and two on Pentasa (mesalazine). Five male patients with late CD who had strictures and required surgical resections did not have levels of antibodies to any of the Signi®cance compared with the healthy control group: *P -0.05; **P -0.01; ***P -0.001; NS s not signi®cant.
collagens above the 95% con®dence limits, but had elevated levels of antibodies to K. pneumoniae. Furthermore, four patients (three males and one female) with late CD were diagnosed as having ®stulae. All four patients had both high CRP and high ESR but did not have elevated levels of antibody to any of the collagens. However, three of these patients did have an immune response to Klebsiella above the 95% con®dence limits.
Correlation coef®cient analysis
There was a signi®cant correlation between IgM anti-K. pneumoniae antibodies and IgM antibodies to type I, III and IV collagens in both early and late CD patients and to type V in early CD patients only (Table 5) . However, there was no signi®cant correlation between IgG anti-K. pneumoniae antibodies and type I, III, IV and V collagen antibodies in either early or late CD ( Table 5 ). Levels of IgA antibodies against K. pneumoniae were also found to correlate with collagen types III and IV in early CD and with type III in late CD patients (Table 5) .
Correlation between anti-K. pneumoniae antibodies and collagen antibodies was also demonstrated in the group of AS patients. IgM and IgG anti-K. pneumoniae antibodies correlated with antibodies to collagen types I and III (Table 5) , whereas in the case of collagen IV only IgG antibodies were found to correlate with antibacterial antibodies.
Coef®cient of variation
The mean coef®cients of variation for levels of IgM, IgG, IgA antibodies to collagen types I, III, IV and V and K. pneumoniae were calculated. For type I collagen, a mean coef®cient of 7% was obtained for IgM, 9% for IgG and 15% for IgA. For type III collagen the coef®cients were 7% for IgM, 6% for IgG and 9% for IgA. For type IV collagen they were 8% for IgM, 8% for IgG and 14% for IgA. For type V collagen they were 9% for IgM, 12% for IgG and 5% for IgA. In addition, a mean coef®cient variation value for K. pneumoniae assays was calculated; the values were 6% for IgM, 10% for IgG and 8% for IgA.
Discussion
This is the ®rst report showing a correlation between the immune responses to a bacterium, namely K. pneumoniae, and self-proteins, namely collagen types I, III, IV and V, in patients having either AS or CD.
This study shows that levels of IgM, IgG and IgA antibodies to collagen types I, III, IV, V and K. pneumoniae were signi®cantly elevated in early and late CD patients compared with healthy controls. Furthermore, IgM and IgG antibodies to type I, III, IV and V collagens were found to be signi®cantly increased in HLA-B27-positive AS patients, whereas IgA levels that were increased above the 95% con®dence limits for the control group were found only for collagen types I, III and V. In addition, levels of anti-K. pneumoniae antibodies of all three classes were elevated in the AS group when compared with the control group. These ®ndings con®rm previous reports of an association between elevated levels of antibodies to K. pneumoniae in CD and AS patients w12,18x. Furthermore, this study is in agreement with recent reports of elevated IgG, IgA and IgM antibodies against collagen types I, III and IV in AS patients w6,19x. Our ®ndings show that AS patients have immune responses to these collagens, which may be responsible for maintaining the characteristic local in¯ammation in AS. Type I collagen is present predominantly in tendons and bones, type III in muscle tissue and types IV and V in the basement membranes of the retina and cornea w8x. AS patients often suffer from acute anterior uveitis, which could be triggered by some of these anti-collagen antibodies w20x.
Molecular mimicry has been proposed as a mechanism involved in the pathogenesis of AS. Amino acid sequence homology between HLA-B27 and the nitrogenase reductase and pullulanase enzymes of K. pneumoniae has been reported w5, 6x. Furthermore, there are similarities in amino acid sequence between the N-terminal end of the extracellular enzyme pullulanase (pulA), in the form of repeats of a tripeptide (Gly-X-Pro), and collagens of types I, III and IV w6x. In the present study there was a good correlation between IgM and IgG antibodies against K. pneumoniae and collagen types I, III and IV in AS patients. This suggests recent infection with this organism. It has been suggested that immune responses to particular serotypes of K. pneumoniae are of importance in HLA-B27-positive patients w21x, class-speci®c IgA antibodies having a pathogenic role, since their titre correlates with disease activity w22, 23x. In this study, we used the K. pneumoniae serotype K50, which has been shown previously by our group w14x and others w21x to produce an elevated antibody response in active AS patients Signi®cance compared with the healthy control group: *P -0.05; **P -0.01; ***P -0.001; NS s not signi®cant. compared with control groups. The immune response to K. pneumoniae was found to be statistically signi®cant in the early and late CD patients investigated in this study, when compared with healthy controls. Furthermore, IgA and IgM antibodies against both K. pneumoniae and collagen types I, III, IV and V correlated in early and late CD patients. However, high or low CRP or high or low ESR was not correlated with levels of antibodies to collagen or K. pneumoniae antibody in early and late CD patients; this may have been due to the low number of patients used in this study, or to a difference in the pathogenic mechanism involved in the initiation of disease and development of persisting chronic ®brotic lesions.
The association of AS with occult bowel disease has been well established. Gut in¯ammation plays a crucial role in the pathogenesis of spondylarthropathies, as ileocolonoscopic studies have demonstrated the presence of gut in¯ammation in 60% of AS patients w9x. In the follow-up study, 25% of those who had chronic in¯am-matory changes on initial biopsy had developed CD w24x. The high prevalence of IBD in spondylarthropathies con®rms the hypothesis that these two disease entities have common pathogenic mechanisms.
An increased immunopathophysiological response to Klebsiella may be important in the initiation and perpetuation of intestinal in¯ammation in IBD, and the increased expression and secretion of pro-in¯ammatory cytokines such as tumour necrosis factor a plays a key role in the immunopathogenesis of CD w25x. Strictures in CD patients contain large amounts of collagen, especially types III w2x and V w1x. These ®ndings are con®rmed indirectly by our studies. Patients who had ileal strictures contained higher levels of antibodies to collagen types I, III and V than healthy controls. However, those who had undergone ileal stricture resection had normal levels of collagen antibodies.
Several independent studies have demonstrated that sulphasalazine is an effective drug in the treatment of AS and is also effective in the treatment of IBD. The drug is known to have antibiotic activity against Klebsiella, and Finnish studies have demonstrated that the titre of anti-Klebsiella antibodies decreases after treatment with sulphasalazine w26x. It has been suggested that the bene®cial effect of the drug could be due to its antiin¯ammatory effects on the gut wall, by normalizing its permeability and by preventing the entrance of antigens through the defective gut wall w9x.
This study provides supportive evidence that there is a correlation between Klebsiella antibodies and collagen types I, III and IV antibodies in both AS and CD. In addition, Klebsiella antibodies and collagen antibodies are increased in both disease groups. Furthermore, persistently elevated immune responses to Klebsiella and to the collagens appear to be present in both early and late CD patients.
Further studies using a larger number of early and late CD patients are required in order to determine the role of K. pneumoniae and its link with collagens in the aetiopathogenesis of CD and AS.
